Avrobio receives orphan drug designation from the european medicines agency for avr-rd-02, an investigational gene therapy for gaucher disease

Avrobio, inc. (nasdaq: avro), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
ADES Ratings Summary
ADES Quant Ranking